Duke University Clinical Trial Shows Promise for Immunotherapy as First-Line Treatment in Colorectal Cancer
Key Insights
Duke University (search) researchers are conducting a clinical trial testing immunotherapy (search) as first-line treatment for the most common type of colorectal cancer (search), where immunotherapy was previously considered ineffective.
A patient with 13 lung tumors from metastatic colon cancer (search) saw dramatic improvement using combination immunotherapy (search) drugs, reducing to just three tumors with the largest being pencil eraser-sized.
The immunotherapy (search) approach retrains the immune system (search) to fight cancer cells while avoiding the severe side effects of chemotherapy (search) such as nausea, fatigue, and hair loss.
A groundbreaking clinical trial at Duke University (search) is demonstrating the potential for immunotherapy (search) to replace chemotherapy (search) as first-line treatment for colorectal cancer (search), offering new hope for patients facing the second leading cause of cancer death in the United States.
The trial focuses on the most common type of colorectal cancer (search), a disease where immunotherapy (search) was previously believed to be unhelpful. Dr. Nicholas DeVito, a medical oncologist and assistant professor at Duke University (search), is leading research that suggests checkpoint inhibitors (search) may one day replace harsh cancer treatments and their toxic side effects as initial therapy for gastrointestinal cancers (search).
Patient Success Story Highlights Treatment Potential
Spencer Laird's case exemplifies the promise of this approach. After receiving an initial colon cancer (search) diagnosis and surgery, his cancer returned with 13 tumors discovered on his lungs. Fearing the debilitating side effects of chemotherapy (search), Laird and his wife CarleyAnn researched alternative treatments and enrolled in Duke's clinical trial testing combination immunotherapy (search) drugs.
The results have been remarkable. Laird now has just three tumors remaining, with the largest measuring only the size of a pencil eraser. He travels eight hours from his home to Durham every two weeks for treatment, a journey he considers worthwhile given the outcomes.
"I think that if I were even still here, I would more than likely be in pretty bad shape, just with the side effects and the sickness and everything that comes along with the chemo and radiation," Laird said. "I just feel very blessed to not have had to do that, to have kind of another way out, not only another way out that doesn't have side effects, but that is working."
Immunotherapy's Mechanism Offers Advantages Over Traditional Treatment
The fundamental difference between immunotherapy (search) and traditional cancer treatment lies in their approach to targeting cancer cells. Chemotherapy (search) targets rapidly-dividing cells throughout the body, which includes both cancerous and healthy cells. This broad targeting contributes to severe side effects including nausea, fatigue, and hair loss.
"With immunotherapy (search), you're retraining your immune system (search)," DeVito explained. "It is learning to fight the cancer off inside your body. This really treats cancer more of like an immune failure, rather than like an infection that you're treating with an anti-biotic like chemotherapy (search)."
Immunotherapy (search) helps train healthy cells to seek and destroy only cancerous cells, potentially eliminating the collateral damage associated with conventional treatments.
Rising Cancer Rates Drive Need for Better Treatments
The research comes at a critical time as colon cancer (search) rates among people younger than 50 are skyrocketing. This demographic shift underscores the urgent need for more effective and tolerable treatment options.
According to DeVito, immunotherapy (search) can give patients with certain late-stage intestinal cancers a better chance at living longer without the side effects and limited success that sometimes accompany chemotherapy (search).
Paradigm Shift in Cancer Treatment Approach
The Duke Cancer Institute research represents a broader shift in how doctors view cancer and approach treatment decisions. For many years, the focus has been to kill or destroy cancer cells with chemotherapy (search) and radiation. The new research suggests a different paradigm where the body's own immune system (search) becomes the primary weapon against cancer.
Dr. Diane Reidy-Lagunes, a medical oncologist at Duke Health (search), noted that this approach may transform treatment for an increasing number of gastrointestinal cancers (search), including colorectal cancer (search), with checkpoint inhibitors (search) potentially serving as first-line therapy.